Health Care • Biotechnology: Pharmaceutical Preparations
$9.33 ▲ +0.18
(+1.97%)
MKT CAP: $351.0M • VOL: 566.9K
52W L $7 52W H $18
ROARABLE / RQD
D- • 40/100
PIOTROSKI
2 / 9
CTNM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $50.0M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$68.1M | -$50.9M | $16.1M |
| Operating Margin % | — | — | 32.2% |
| Net Income (GAAP) | -$60.0M | -$42.3M | $22.7M |
| EBITDA (Normalized) | -$67.9M | -$50.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$55.3M | -$32.8M | $19.3M |
| Capital Expenditures (CapEx) | $231.0K | $514.0K | — |
| Free Cash Flow (FCF) | -$55.5M | -$33.4M | $19.3M |
| FCF Margin % | — | — | 38.7% |
| Return on Invested Capital (ROIC %) | -29.0% | -22.8% | — |
| Cash & Short-Term Equivalents | $75.6M | $21.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $261.0M | $198.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CTNM.